Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Jounce Therapeutics shares plunge on scant details about its Phase 1/2 ICONIC trial

The biotech's preliminary data evaluates its lead drug candidate JTX-2011
Joust's shares are trading sharply lower in morning trade

Shares in Jounce Therapeutics (NASDAQ:JNCE) plunged in early trade after the biotech revealed plans to present preliminary data from its Phase 1/2 ICONIC trial at this year’s American Society of Clinical Oncology annual meeting in Chicago on June 2.

But investors reacted poorly to the dearth of information about the drug trial in the announcement, sending shares down 34% to US$11.57.

The huge sell-off is owed to Jounce’s lack of extensive data on the trial, which is evaluating the worth of its lead drug candidate JTX-2011, alone and in combination with Bristol-Myer Squibb’s (NYSE:BMY) Opdivo (nivolumab) to treat gastric cancer, triple negative breast cancer, head and neck squamous cell cancer and non-small cell lung cancer in late-stage patients.

Elizabeth Trehu, chief medical officer of Jounce Therapeutics, reported that JTX-2011 is “well-tolerated alone and in combination with nivolumab" and has provided evidence of tumor reductions in heavily pre-treated patients who have failed all available therapies.

View full JNCE profile View Profile

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use